Welcome to our dedicated page for Perspective Therapeutics news (Ticker: CATX), a resource for investors and traders seeking the latest updates and insights on Perspective Therapeutics stock.
Perspective Therapeutics develops radiopharmaceutical candidates for cancer using proprietary Lead-212 (212Pb) technology and specialized targeting moieties. Its updates center on a theranostic approach that pairs targeted alpha therapy with complementary imaging diagnostics.
Recurring CATX news covers clinical and conference updates for VMT-α-NET in SSTR2-expressing neuroendocrine tumors, VMT01 for melanoma, and PSV359 for solid tumors, along with business results, financing activity, manufacturing infrastructure, 212Pb generator-enabled finishing facilities, and corporate presentations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PharmaLogic Holdings Corp., a contract development organization, has signed a Master Services Agreement with Viewpoint Molecular Targeting, Inc. (NYSE AMERICAN: CATX) for the development of theranostics VMT-01 and VMT-α-NET. These radiopharmaceuticals are aimed at diagnosing and treating metastatic melanoma and neuroendocrine tumors. PharmaLogic will supply doses for Perspective's clinical trials, leveraging its expertise in radiopharmaceuticals. This collaboration is expected to enhance the precision of cancer treatments, with clinical trials set to begin enrollment soon, and preliminary results anticipated later this year.